TABLE 2
FROM:
Commentary: From Scarcity to Abundance: Pandemic Vaccines and Other Agents for "Have Not" Countries
David S Fedson and Peter Dunnill
BACK TO ARTICLETable 2. Hypothetical number of people who could be vaccinated with 3 months' production of conventional egg-based H5N1 or rHAO H5 influenza vaccines*
Amount of HA antigen per dose ( g HA)
| Egg-based vaccine † | rHAO vaccine ‡ |
|---|---|---|
| 10 | 132 M | 1.3 B |
| 3.75 | 351 M | 3.4 B§ |
* The estimates for both vaccines assume that two doses of adjuvanted vaccine would be required for each person. M indicates million; B indicates billion.
† The estimate for egg-based production assumes that yields of reverse genetics-engineered H5N1 vaccine viruses would be 33% of the yields for seasonal vaccine viruses and that the global capacity to produce egg-based seasonal vaccines is 350 million doses (see reference 8).
‡ The estimate for rHAO production uses yields that are reduced to 25% of those estimated from the company's pilot studies and assumes that 25% (500,000 liters) of the global pharmaceutical bioreactor capacity (2,000,000 liters) could be harnessed for rHAO vaccine production (see reference 8).
§ In 2005 the world population was estimated to be 6.45 billion people.
